Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 17/20 | 0.58 |
| ▸ | SLC5A1 | P13866 | 8/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12731352 | 1.00 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11TSHR | |
| SCHEMBL14644609 | 1.00 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11TSHR | |
| SCHEMBL29657331 | 1.00 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11TSHR | |
| SCHEMBL18522185 | 1.00 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11TSHR | |
| SCHEMBL16730394 | 1.00 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11TSHR | |
| SCHEMBL10228164 | 1.00 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11TSHR | |
| SCHEMBL18214898 | 1.00 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11TSHR | |
| SCHEMBL19182955 | 1.00 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11TSHR | |
| SCHEMBL15030927 | 1.00 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11TSHR | |
| SCHEMBL17065784 | 1.00 | SLC5A2 (0.58) | SLC5A2SLC5A1ADRA2ASLC5A11TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161912-A1 | PREPARATION OF HIGHLY PURE AMORPHOUS DAPAGLIFLOZIN | KRKA, d.d., Novo mesto (SI) | 2023-04-12 | — | — | EP | claimed |
| US-20190144411-A1 | Process for the preparation of (1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl) methyl]phenyl]-D-glucitol and its solvate thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2019-05-16 | — | — | US | claimed |
| US-20170029398-A1 | PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-{4-CHLORO-3-4[(4-ETHOXYPHENYL)METHYL]PHENYL]-GLUCITOL AND ITS SOLVATE THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-02-02 | — | — | US | claimed |
| EP-3114115-A2 | PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-[4-CHLORO-3-[(4-ETHOXYPHENYL)METHYL]PHENYL]-D-GLUCITOL AND ITS SOLVATE THEREOF | MSN Laboratories Private Limited (IN) | 2017-01-11 | — | — | EP | claimed |
| WO-2015132803-A2 | PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-[4-CHLORO-3-[(4-ETHOXYPHENYL)METHYL]PHENYL]-D-GLUCITOL AND ITS SOLVATE THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-09-11 | — | — | WO | claimed |
| EP-4389733-A1 | METHOD FOR PREPARING 5-BROMO-2-CHLORO-BENZOIC ACID AS RAW MATERIAL IN HYPOGLYCEMIC DRUG SYNTHESIS | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2024-06-26 | — | — | EP | disclosed |
| EP-4161912-A1 | PREPARATION OF HIGHLY PURE AMORPHOUS DAPAGLIFLOZIN | KRKA, d.d., Novo mesto (SI) | 2023-04-12 | — | — | EP | disclosed |
| US-11565990-B2 | Preparation of 4-bromo-2-(4′-ethoxyphenyl)-1-chlorobenzene | WISDOM PHARMACEUTICAL CO., LTD (CN) | 2023-01-31 | — | — | US | disclosed |
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2023-01-10 | — | — | US | disclosed |
| WO-2021260617-A1 | AN IMPROVED PROCESS FOR PREPARATION OF DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE | HIKAL LIMITED (IN) | 2021-12-30 | — | — | WO | disclosed |
| US-20210323939-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | LAURUS LABS LIMITED (IN) | 2021-10-21 | — | — | US | disclosed |
| EP-2069374-B2 | CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2021-07-28 | — | — | EP | disclosed |
| WO-2008002824-A1 | CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004336-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004336-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| WO-2007093610-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093610-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
| EP-1506211-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029398-A1 | PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-{4-CHLORO-3-4[(4-ETHOXYPHENYL)METHYL]PHENYL]-GLUCITOL AND ITS SOLVATE THEREOF | ADH1C, ALG1, UGGT1 | SLC5A2 94/4885SLC5A1 8/4885ADRA2A 2580/4885 |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1603/4885 |
| US-20190144411-A1 | Process for the preparation of (1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl) methyl]phenyl]-D-glucitol and its solvate thereof | ADH1C, ALG1, UGGT1 | SLC5A2 93/4885SLC5A1 9/4885ADRA2A 2638/4885 |
| US-11565990-B2 | Preparation of 4-bromo-2-(4′-ethoxyphenyl)-1-chlorobenzene | SLC5A2, SLC5A1, DPP4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 2271/4885 |
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 2862/4885 |
| US-20210323939-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | SLC5A1, SLC5A2, DPP4 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 2269/4885 |
| US-20080004336-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | SLC5A2, SLC5A1, GLP1R | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.